Table 1 Baseline characteristics of the meta-analyzed study cohort, stratified by trial

From: From trial data to personalized medicine: a validated framework with an application to Crohn’s disease

Drug Class Trial Alias

Anti-Il-12/23

Anti-Integrin

Anti-TNF

CERTIFI

UNITI1

UNITI2

ENACT

GEMINI2

GEMINI3

ACCENT

CLASSIC

EXTEND

   

PRECISE1

PRECISE2

SONIC

Trial NCT identifier

NCT00771667

NCT01369329

NCT01369342

NCT00032786

NCT00783692

NCT01224171

NCT00207662

NCT00055523 NCT00055497

NCT00348283

NCT00291668

NCT00552058

NCT02499783

NCT00152490

NCT00152490

NCT00152425

Year

2008

2011

2011

2001

2008

2010

1999

2002

2006

2006

2008

2015

2003

2003

2005

Included cohort size

252

502

416

875

1050

407

190

73

64

60

409

102

593

559

151

Treatment Group

               

Active

126 (50%)

252 (50%)

209 (50%)

698 (80%)

915 (87%)

205 (50%)

190 (100%)

73 (100%)

64 (100%)

30 (50%)

210 (51%)

102 (100%)

298 (50%)

559 (10%)

151 (100%)

Placebo

126 (50%)

250 (50%)

207 (50%)

177 (20%)

135 (13%)

202 (50%)

..

..

..

30 (50%)

199 (49%)

..

295 (50%)

..

..

Age

39 ( ± 13)

37 ( ± 12)

39 ( ± 13)

38 ( ± 13)

36 ( ± 12)

38 ( ± 13)

37 ( ± 12)

38 ( ± 11)

37 ( ± 11)

33 ( ± 12)

37 ( ± 12)

33 ( ± 10)

37 ( ± 12)

39 ( ± 13)

36 ( ± 13)

Female Sex

107 (42%)

224 (45%)

189 (45%)

372 (43%)

492 (47%)

176 (43%)

79 (42%)

35 (48%)

24 (38%)

47 (78%)

181 (44%)

67 (66%)

259 (44%)

271 (48%)

77 (51%)

BMI

26 ( ± 7.3)

22 ( ± 0.58)

25 ( ± 6.2)

25 ( ± 5.6)

24 ( ± 6.0)

24 ( ± 5.7)

24 ( ± 4.7)

26 ( ± 6.0)

25 ( ± 4.6)

20 ( ± 2.7)

24 ( ± 4.9)

19 ( ± 2.7)

24 ( ± 5.3)

24 ( ± 5.1)

25 ( ± 5.5)

Baseline CDAI

320 ( ± 67)

320 ( ± 60)

300 ( ± 56)

300 ( ± 61)

320 ( ± 69)

310 ( ± 53)

310 ( ± 54)

290 ( ± 52)

320 ( ± 69)

290 ( ± 58)

290 ( ± 60)

270 ( ± 48)

300 ( ± 61)

300 ( ± 59)

290 ( ± 62)

CRP (mg/L)

21 ( ± 28)

18 ( ± 23)

16 ( ± 20)

19 ( ± 25)

21 ( ± 26)

18 ( ± 22)

20 ( ± 23)

13 ( ± 18)

20 ( ± 21)

31 ( ± 21)

19 ( ± 26)

24 ( ± 25)

18 ( ± 25)

20 ( ± 28)

25 ( ± 28)

History of Anti-TNF Use

252 (100%)

479 (95%)

135 (32%)

348 (40%)

649 (62%)

306 (75%)

0 (0%)

2 (3%)

31 (48%)

1 (2%)

0 (0%)

0 (0%)

161 (27%)

156 (28%)

0 (0%)

Steroid Use

134 (53%)

232 (46%)

172 (41%)

356 (41%)

532 (51%)

213 (52%)

94 (49%)

21 (29%)

6 (9%)

14 (23%)

179 (44%)

31 (30%)

235 (40%)

205 (37%)

58 (38%)

Imm. use

64 (25%)

166 (33%)

143 (34%)

330 (38%)

341 (32%)

137 (34%)

44 (23%)

19 (26%)

26 (41%)

17 (28%)

139 (34%)

61 (60%)

235 (40%)

230 (41%)

0 (0%)

Ileal Disease

182 (72%)

407 (81%)

335 (81%)

675 (77%)

752 (72%)

310 (76%)

155 (82%)

47 (64%)

48 (75%)

42 (70%)

286 (70%)

82 (80%)

425 (72%)

378 (68%)

104 (69%)

  1. Characterization of baseline covariates of included studies. Placebo arms from ACCENT, CLASSIC, EXTEND, NCT02499783, PRECISE2, and SONIC studies were not included due to the absence of a 6-week parallel arm placebo group (see Supplementary Fig. 1). Continuous variables are reported as mean (standard deviation) and binary variables are reported as count (proportion). CRP c-reactive protein, TNF tumor necrosis factor.
Back to article page